<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963947</url>
  </required_header>
  <id_info>
    <org_study_id>MAL-BEL-2018-01</org_study_id>
    <nct_id>NCT03963947</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With House Dust Mites</brief_title>
  <official_title>Observational Prospective Study to Assess the Safety and Effectiveness of Beltavac® Polymerized With House Dust Mites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alfons Malet i Casajuana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Probelte Pharma S.L.U.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Medico Teknon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional Study to Assess the Safety and Effectiveness Profile of a SCIT Therapy
      With Beltavac® Polymerised With House Dust Mite in pediatric allergic patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective open multi-center non-interventional study assess the safety and
      effectiveness profile of the subcutaneous allergen-specific immunotherapy with Beltavac
      polymerized with house dust mite pediatric allergic patients in routine medical care.

      Patients receive a rush schedule administration every month for a year. They attend at least
      5 study visits to inform about the adverse reactions, the self reported symptoms and the
      medication intake.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of treatment-related local and systemic reactions</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined symtom and medication score of Rhinoconjunctivitis</measure>
    <time_frame>1 Year</time_frame>
    <description>The score will be calculated as a sum of the symptoms score (0-3) and medication score (0-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined symtom and medication score of Asthma</measure>
    <time_frame>1 Year</time_frame>
    <description>The score will be calculated as a sum of the symptoms score (0-3) and medication score (0-3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue Scale Score</measure>
    <time_frame>1 Year</time_frame>
    <description>Psycometric scale that assesses the global allergic disease discomfort. It is a 10 cm line representing severity from 0:&quot;no symptoms&quot; to 10 &quot;highest level of symptoms&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgE and IgG4 specific quantification</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Rhinoconjunctivitis With or Without Allergic Asthma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Beltavac® Polymerized with house dust mites</intervention_name>
    <description>Adminstration of Beltavac® Polymerized with house dust mites according to the routine clinical practice</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from 3 to 11 years, who suffer from allergic rhinitis or rhinoconjunctivitis
        associated with or not with asthma caused by house dust mites
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients from 3 to 11 years suffering from a clinically relevant Dermatophagoides
             farinae and Dermatophagoides pteronyssinus induced allergic rhinitis or
             rhinoconjunctivitis associated with or not with asthma

          -  Positive skin testing

          -  Positive Serum-Specific IgE determination

          -  Parental or legal representative informed consent

          -  Clinical sintomatology on the inclusion period

        Exclusion Criteria:

          -  Patients suffering from acute or chronic infections or inflammations

          -  Patients suffering from uncontrolled and severe asthma

          -  Patients with a known autoimmune disease

          -  Patients with active malignant disease

          -  Patients requiring beta-blockers

          -  Patients having any contraindication for the use of adrenaline

          -  Patients with previous immunotherapy with this allergen or another allergen with
             cross-reaction

          -  Patients with immunotherapy treatment at the time of inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alfons Malet, DM</last_name>
    <phone>+34 678877673</phone>
    <email>10655amc@comb.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inmaculada Buendía, DVM</last_name>
    <phone>+34 968 858 577</phone>
    <email>inmabuendia@probeltepharma.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Teknon Medical Center</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfons Malet</last_name>
      <phone>678 87 76 73</phone>
      <email>10655amc@comb.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>May 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2019</study_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centro Medico Teknon</investigator_affiliation>
    <investigator_full_name>Alfons Malet i Casajuana</investigator_full_name>
    <investigator_title>Head of Allergy Service in Teknon Medical Center</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

